—Data Presented at 2022 EASL International Liver ConferenceTM and First International Extracellular Matrix Pharmacology Congress—
TEL AVIV, Israel, June 27, 2022 /PRNewswire/ — Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today reported on two recent presentations at important scientific meetings. The presentations included preclinical data that support the role of the soluble protein CCL24 in the pathophysiology of liver diseases such as primary sclerosing cholangitis (PSC), and also indicate that Chemomab’s CCL24 neutralizing antibody CM-101 demonstrates translatable patterns of extracellular matrix (ECM) remodeling in preclinical and clinical studies.
At EASL: The International Liver Congress™ 2022, Chemomab presented data1 from a combination of single-cell and spatial transcriptomics methods that enabled an in-depth analysis of relevant subpopulations and pathways regulated by CCL24 in fibroinflammatory liver disease. The analysis revealed unique resident liver macrophage subpopulations as the major source of CCL24 in the injured peribiliary area in an experimental PSC model. The analysis also showed that treatment with CM-101 interfered with core PSC pathways, including inhibiting ECM-related pathways and the recruitment and presence of monocytes and macrophages.
At the First International Extracellular Matrix Pharmacology Conference, Chemomab presented clinical and animal model data2 demonstrating that treatment with its CCL24 neutralizing antibody CM-101 attenuates remodeling of ECM key proteins. ECM deposition is known to be affected by fibroblast activation and epithelial cell activity, key cell populations that have been shown to be involved in the pathophysiology of PSC and that are closely related to CM-101’s mechanism of action. Importantly, this dataset supports the translation of these results from relevant animal models into the design of Chemomab’s clinical studies assessing CM-101 as a potential treatment for PSC, including potentially applying findings using experimental models of ECM remodeling in the liver to the use of a translatable profile of serum biomarkers in patients.
“We welcome the opportunity to present validating data on the central role of CCL24 in the pathophysiology of fibroinflammatory liver disease and the corresponding ability of CM-101 to attenuate key biomarkers associated with this pathophysiology,” noted Adi Mor, PhD, co-founder and Chief Scientific Officer of Chemomab. “These studies are valuable for informing our clinical trials in PSC and other disorders, and for further highlighting the significant potential of our unique approach.”
1 – Combination of Whole Liver Single Cell RNA Sequencing and Spatial Transcriptomics Reveals Specific Cell Sub-Populations and Pathways Regulated by CCL24, Abstract Identifier: OS02, June 23, 2022
2 – CCL24 Inhibition by CM-101 Attenuates Extracellular Matrix and Fibrotic Biomarkers in Both Patients and Experimental Murine Models, Abstract ID:155, Udi Gluschnaider, Amnon Peled, Michal Segal-Salto, Avi Katav, Omer Levi, Adi Mor, Ophir Hay, Inbal Mishalian, Devorah Olam and Raanan Greenman, June 23, 2022